Results 11 to 20 of about 9,825 (155)

Reimagining Hepatitis C Elimination: Time for Actions, Not Targets. [PDF]

J Int AIDS Soc
Journal of the International AIDS Society, Volume 29, Issue 8, August 2026.
Klein MB, Kronfli N, Young J.
europepmc   +2 more sources

Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response. [PDF]

J Viral Hepat
ABSTRACT Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalized populations. This study developed and internally validated a machine learning model to predict short‐duration (4–6 weeks) DAA response using baseline clinical factors with potential to improve ...
Carson JM, Barbieri S, Verich A, Tu E, Lloyd A, Dore GJ, Matthews GV, Martinello M.   +7 more
europepmc   +2 more sources

Effect of Sofosbuvir (Sovaldi) on the Fundic Mucosa of Adult Male Albino Rats and the Possible Protective Role of Fucoidan: Histological, Histochemical, and Immunohistochemical Study [PDF]

The Egyptian Journal of Histology, 2022
Background: Sofosbuvir (SOF) is a hopeful remedy for chronic hepatitis C virus infection. However, it records some unfavorable influences on gastrointestinal tract.
Dalia Elghazouly, Rania Yassien
doaj   +1 more source

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian-Born Patients. [PDF]

J Viral Hepat
ABSTRACT The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016 ...
Taye BW, Valery PC, Strasser SI, Weltman M, Thompson AJ, Levy MT, Leggett B, Zekry A, Rong YJ, Sinclair M, George J, Sievert W, MacQuillan G, Tse E, Wade A, Cheng W, Roberts SK, Clark PJ.   +17 more
europepmc   +2 more sources

Successful treatment of vertically acquired Hepatitis C in a child using direct-acting antiviral therapy administered via gastrojejunal tube: A case report. [PDF]

JPGN Rep
Abstract Hepatitis C virus (HCV) remains a significant global health burden, with vertical transmission being the primary route of infection in children. Direct‐acting antivirals (DAAs) have transformed HCV treatment in pediatrics, but limited data exist on their administration in medically complex children who are dependent on enteral tubes. We report
Chen C, Gibson L, Squires J.
europepmc   +2 more sources

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D

Pakistan Armed Forces Medical Journal, 2020
Objective: To assess the safety and efficacy of Sofosbuvir based Antiviral regimens for chronic hepatitis C virus infected patients with chronic kidney disease stage 3 to stage 5D on haemodialysis. Study Design: Quasi experimental study.
Nauman Kashif, Zahid Farooq Baig, Shahzad Ashraf   +2 more
doaj   +4 more sources

Efficacy and Adverse Effects of Sofosbuvir-Based Therapies (Double and Triple Regimens) in Chronic HCV Patients [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2017
Background and study aim: Egypt has the highest prevalence of hepatitis C virus in the world and it is about14.7 %. Until 2012, the combination of pegylated interferon-α and ribavirin was the standard of care in CHC.
Amal Jouda, Hosam Dawod, Nahla Elgammal
doaj   +1 more source

The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Background and aim There have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency against the hepatitis C virus (HCV).
Waleed Ismail, Amr Hanafy, Mohammed Abdelsattar   +2 more
doaj   +1 more source

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

Український Журнал Нефрології та Діалізу, 2020
Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to ...
M. Mostafi, M. Jabin, Z. Chowdhury, M.U. Khondoker, S.M. Ali, R. Tamanna, R. Rezwan, S.B. Alomgir   +7 more
doaj   +1 more source